NCT00884676 - Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2013

Study Completion Date

July 31, 2015

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

Ixabepilone

"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~* Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~* Schedule B: Day 1 of each 3-week cycle."

DRUG

Sunitinib

For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1

Trial Locations (1)

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami